The effect of fenfluramine on obese, maturity-onset diabetic patients.
In 38 obese maturity-onset diabetic patients the effect of fenfluramine therapy on carbohydrate tolerance was compared to placebo therapy in a double blind trial. Fenfluramine therapy did not affect weight loss, or fasting glucose levels but produced a slight but significant improvement in glucose tolerance. This improvement was not correlated with any change in body weight or insulin secretion.
D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D050260:Carbohydrate Metabolism; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005277:Fenfluramine / Q000627:therapeutic use*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity
D001786:Blood Glucose; D007328:Insulin; D005277:Fenfluramine